SEARCH

SEARCH BY CITATION

References

  • 1
    Raoul JL, Bourguet P, Bretagne JF, Duvauferrier R, Coornaert S, Darnault P, Ramée A, et al. Hepatic artery injection of I-131 Lipiodol. Part I: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541545.
  • 2
    Bhattacharya S, Novell JR, Winslet MC, Hobbs KEF. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994; 81: 15631571.
  • 3
    Raoul JL, Heresbach D, Bretagne JF, Bentue-Ferrer D, Duvauferrier R, Bourguet P, Messner M, et al. Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of adriamycin. Cancer 1992; 70: 585590.
  • 4
    Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35: 17821787.
  • 5
    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918928.
  • 6
    Pelletier G, Roche A, Ink O, Anciaux ML, Derby S, Rougier P, Lenoir C, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181184.
  • 7
    Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 13231334.
  • 8
    Bretagne JF, Raoul JL, Bourguet P, Duvauferrier R, Deugnier Y, Faroux R, Ramée A, et al. Hepatic artery injection of 1-131 Lipiodol. Part II: preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 547550.
  • 9
    Yoo HS, Lee JT, Kim KW, Kim BS, Choi HJ, Lee KS, Park CH, et al. Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled oil. Cancer 1991; 68: 18781884.
  • 10
    Novell R, Hilson A, Hobbs K. Ablation of recurrent primary liver cancer using 1311-Lipiodol. Postgrad Med J 1991; 67: 393395.
  • 11
    Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, Ho KC, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipio-dol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35: 13131318.
  • 12
    Raoul JL, Bretagne JF, Caucanas JP, Pariente FA, Boyer J, Paris JC, Michel H, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992; 69: 346352.
  • 13
    Yoo HS, Park CH, Suh JH, Lee JT, Kim DI, Kim BS, Madsen MT, et al. Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. Cancer Chemother Pharmacol 1989; 23 (suppl): S54S58.
  • 14
    Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 12561261.
  • 15
    Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, Kim CY. Hepatic tumors: predisposing factors for complications of transcatheter chemoembolization. Radiology 1996; 198: 3340.
  • 16
    Spreafico C, Marchiano A, Regalia E, Frigerio LF, Garbagnati F, Andreola S, Milella M, et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 1994; 192: 687690.
  • 17
    Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8: 11081114.
  • 18
    Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P, Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. AmJ Surg 1992; 163: 387394.
  • 19
    Farinati F, Demaria N, Marafin C, Herszenyi L, Delprado S, Rinaldi M, Perini L, et al. Unresectable hepatocellular carcinoma in cirrhosis – survival, prognostic factors, and unexpected side effects after transcatheter chemoembolization. Dig Dis Sci 1996; 41: 23322339.
  • 20
    Bruix J, Castells A, Montanyà X, Calvet X, Brù C, Ayuso C, Jover L, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994; 20: 643650.
  • 21
    Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R. Is chemoembolization of value in inoperable primary hepatocellular carcinoma. Gut 1996; 38: 125128.
  • 22
    Vetter D, Wenger JJ, Fratté S, Czernichow B, Bronowicki JP, Doffoël M. Incidence des thromboses artérielles chez les patients traités par chimioembolisation Lipiodolée pour un carcinome hepatocellulaire en fonction de l'antimitotique utilise [Abstract]. Gastroenterol Clin Biol 1992; 16: 35A.
  • 23
    Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A, Nakamura T, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 1989; 106: 8186.